0000899243-22-017876.txt : 20220512 0000899243-22-017876.hdr.sgml : 20220512 20220512210329 ACCESSION NUMBER: 0000899243-22-017876 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220510 FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spurr Robert CENTRAL INDEX KEY: 0001543795 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 22919859 MAIL ADDRESS: STREET 1: C/O BAUSCH HEALTH COMPANIES INC. STREET 2: 400 SOMERSET CORPORATE BLVD. CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bausch Health Companies Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 BUSINESS PHONE: 514-744-6792 MAIL ADDRESS: STREET 1: 2150 ST. ELZEAR BLVD. WEST STREET 2: LAVAL CITY: QUEBEC STATE: A8 ZIP: H7L 4A8 FORMER COMPANY: FORMER CONFORMED NAME: Valeant Pharmaceuticals International, Inc. DATE OF NAME CHANGE: 20100928 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-10 0 0000885590 Bausch Health Companies Inc. BHC 0001543795 Spurr Robert 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 0 1 0 0 President, U.S. Businesses Common Shares, No Par Value 2022-05-10 4 M 0 8643 A 99149 D Common Shares, No Par Value 2022-05-10 4 M 0 13592 A 112741 D Restricted Share Units 2022-05-10 4 A 0 8643 A 2022-05-10 Common Shares, No Par Value 8643 0 D Restricted Share Units 2022-05-10 4 M 0 8643 9.40 D 2022-05-10 Common Shares, No Par Value 0 0 D Restricted Share Units 2022-05-10 4 A 0 13592 A 2022-05-10 Common Shares, No Par Value 13592 0 D Restricted Share Units 2022-05-10 4 M 0 13592 9.40 D 2022-05-10 Common Shares, No Par Value 0 0 D Reflects an award of performance-based Restricted Share Units ("PSUs"), previously granted to the reporting person on February 26, 2020, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on February 26, 2023, subject to the reporting person's continuous service. Reflects an award of PSUs, previously granted to the reporting person on March 3, 2021, that was earned upon the certification of performance metrics applicable to such PSUs. The earned PSUs will vest on March 3, 2023, subject to the reporting person's continuous service. Each PSU converts into common shares, no par value, of the Issuer on a one-for-one basis. /s/ Brianna M. Cetrulo, attorney-in-fact 2022-05-12 EX-99 2 attachment1.htm EX-99 DOCUMENT

                        POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes
and appoints each of Brianna Cetrulo, Mina Thomas, and Deborah Klein,
or any of them signing singly, and with full power of substitution,
the undersigned's true and lawful attorney-in-fact to:

(1)	prepare, execute in the undersigned's name and on the
undersigned's behalf, and submit to the U.S. Securities and Exchange
Commission (the "SEC") a Form ID, including amendments thereto, and
any other documents necessary or appropriate to obtain codes and passwords
enabling the undersigned to make electronic filings with the SEC of reports
required by Section 16(a) of the Securities Exchange Act of 1934 (the
"Exchange Act") or any rule or regulation of the SEC;

(2)	execute for and on behalf of the undersigned, in the
undersigned's capacity as a director and/or officer of Bausch Health
Companies Inc. (the "Company"), Forms 3, 4 and 5 in accordance with
Section 16(a) of the Exchange Act and the rules thereunder;

(3)	do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and
execute any such Form 3, 4 and 5 complete and execute any amendment
or amendments thereto, and timely file such form with the SEC and any
stock exchange or similar authority; and

(4)	take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-fact, may
be of benefit to, in the best interest of, or legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power
of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in such attorney in
fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes
as the undersigned might or could do if personally present, with full
power of substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorney-in-fact's substitute
or substitutes, shall lawfully do or cause to be done by virtue of this
power of attorney and the rights and powers herein granted.  The undersigned
acknowledges that the foregoing attorneys in fact, in serving in such
capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect
to the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.


       [REMAINDER OF PAGE INTENTIONALY LEFT BLANK)


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed on the date set forth below.

By:  /s/ Robert Spurr

      Date: May 3, 2022